European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Go back to European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors| Gilead Sciences (NASDAQ: GILD) | Delayed: 130.86 +0.52 (0.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.34 | 52 Week High | $108.63 | |||
| Open | $129.22 | 52 Week Low | $71.39 | |||
| Day High | $131.07 | P/E | 72.30 | |||
| Day Low | $127.61 | EPS | $1.81 | |||
| Volume | 6,179,987 | |||||
